Ionis Pharmaceuticals Inc (NASDAQ:IONS) Stock Holdings Lifted by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. raised its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 71.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 308,002 shares of the company’s stock after buying an additional 128,469 shares during the period. Nikko Asset Management Americas Inc. owned approximately 0.22% of Ionis Pharmaceuticals worth $19,795,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Ionis Pharmaceuticals by 0.6% in the first quarter. FMR LLC now owns 20,633,698 shares of the company’s stock valued at $1,674,837,000 after buying an additional 123,948 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Ionis Pharmaceuticals by 95.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 137,876 shares of the company’s stock valued at $6,402,000 after purchasing an additional 67,200 shares during the period. Dynamic Capital Management Ltd acquired a new stake in Ionis Pharmaceuticals during the 1st quarter valued at $495,000. Polianta Ltd acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at $1,079,000. Finally, Belpointe Asset Management LLC acquired a new stake in Ionis Pharmaceuticals during the 1st quarter valued at $120,000. 83.17% of the stock is currently owned by institutional investors.

Several brokerages have issued reports on IONS. Piper Jaffray Companies set a $75.00 target price on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, May 24th. ValuEngine downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Cantor Fitzgerald reissued a “hold” rating and set a $68.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, April 24th. Evercore ISI set a $76.00 target price on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday. Finally, BMO Capital Markets cut their target price on shares of Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 24th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $67.78.

In other news, Director Frederick T. Muto sold 15,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $65.29, for a total transaction of $979,350.00. Following the transaction, the director now directly owns 24,794 shares in the company, valued at approximately $1,618,800.26. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $70.25, for a total transaction of $702,500.00. Following the transaction, the chief executive officer now owns 79,634 shares in the company, valued at $5,594,288.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,210 shares of company stock worth $2,650,844. 2.40% of the stock is currently owned by corporate insiders.

Shares of Ionis Pharmaceuticals stock traded up $0.29 on Friday, hitting $68.59. 49,416 shares of the company traded hands, compared to its average volume of 1,151,313. The stock’s 50-day moving average is $65.34. The company has a debt-to-equity ratio of 0.47, a quick ratio of 9.36 and a current ratio of 9.40. Ionis Pharmaceuticals Inc has a 12-month low of $43.27 and a 12-month high of $86.58. The company has a market cap of $9.66 billion, a P/E ratio of 23.18 and a beta of 2.07.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.26. Ionis Pharmaceuticals had a net margin of 47.74% and a return on equity of 44.03%. The business had revenue of $164.00 million for the quarter, compared to analysts’ expectations of $145.31 million. During the same period in the previous year, the company posted ($0.29) EPS. Ionis Pharmaceuticals’s revenue was up 39.0% on a year-over-year basis. Equities analysts expect that Ionis Pharmaceuticals Inc will post -0.23 EPS for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Read More: Investing in Growth Stocks

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.